LWCFA
AMED

Loring Wolcott & Coolidge Fiduciary Advisors’s Amedisys AMED Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6
Closed -$1K – 751
2021
Q2 		$1K Buy
+6
New +$1.57K ﹤0.01% 922

Other funds holding AMED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's AMED Position: Q3 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Amedisys (AMED) in Q3 2021, closing a stake of 6 shares — an estimated $1K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in AMED in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 352 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 6 Amedisys shares in Q3 2021, an estimated $1K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Amedisys in Q2 2021 and held it in 1 quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Amedisys position peaked at $1K in Q2 2021.
  • 352 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.